Patents by Inventor Alexander W. Langston

Alexander W. Langston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Regulating gene expression using retinoids with CH.sub.2 OH or related groups at the side chain terminal position
    Patent number: 5962534
    Abstract: For the first time, certain retinoids with a side chain terminal CH.sub.2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.
    Type: Grant
    Filed: July 3, 1997
    Date of Patent: October 5, 1999
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Lorraine J. Gudas, Charles Achkar, Jochen Buck, Alexander W. Langston, Fadila Derguini, Koji Nakanishi
  • Regulating gene expression using retinoids with Ch.sub.2 OH or related groups at the side chain terminal position
    Patent number: 5786391
    Abstract: For the first time, certain retinoids with a side chain terminal CH.sub.2 OH group or ester or ether thereof or aldehyde rather than a side chain terminal COOH group and substitution at the 4-position have been indicated to bind to nuclear receptors and to be biologically active in inducing cell differentiation of normal and tumor cells. These compounds activate gene expression through binding to nuclear receptor proteins. These compounds induce differentiation in normal and cancer cells and are useful for treating leukemias, and lymphomas, squamous cell carcinomas, deep (cystic) acne, psoriasis and photodamaged or aging skin. These compounds have stability and in vitro half-life advantages over and solubility differences from all-trans-retinoic acid and activity advantages over 13-cis retinoic acid.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: July 28, 1998
    Assignees: Cornell Research Foundation, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Lorraine J. Gudas, Charles Achkar, Jochen Buck, Alexander W. Langston, Fadila Derguini, Koji Nakanishi